ReviewThe Korean journal of internal medicine2026
Heart failure with preserved ejection fraction in women: a sex-specific clinical review.
Review in The Korean journal of internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) affects approximately half of the current heart failure population and demonstrates marked sex-related differences in pathophysiology, clinical presentation, and therapeutic response. These distinctions reflect the divergent biological pathways that shape disease expression in women and men. In women, disease expression is frequently linked to cardiometabolic stress, vascular dysfunction, and heightened ventricular-arterial coupling, often manifesting as concentric remodeling and a pronounced symptom burden. By contrast, men more commonly exhibit an ischemia-associated phenotype characterized by adverse remodeling and diffuse myocardial fibrosis. These biological differences influence the clinical presentation, biomarker interpretation, imaging findings, and long-term outcomes. Although most pharmacological therapies demonstrate broadly comparable efficacy between sexes, selected neurohormonal interventions and lifestyle-based strategies may yield differential benefits, underscoring the importance of sex- and phenotype-informed management. The recognition of sex-related heterogeneity in HFpEF may refine diagnostic algorithms, improve therapeutic targeting, and inform the design of future precision-based clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.